Further Weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) Drops 12% This Week, Taking Five-year Losses to 54%

Simply Wall StSep 27 08:11 ET

Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsSep 16 09:32 ET · Ratings

EyePoint Pharmaceuticals Announces Board Changes and New Appointments

TipRanksSep 4 07:27 ET

Express News | EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

ReutersSep 4 07:00 ET

Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15

Moomoo NewsAug 28 05:31 ET · Ratings

Jefferies Initiates EyePoint Pharmaceuticals at Buy

MT NewswiresAug 28 05:15 ET